Pharmacokinetics of Asciminib When Taken With Imatinib or With Food-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics of Asciminib When Taken With Imatinib or With Food

Published:2021-10-05 Issue:2 Volume:11 Page:207-219
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Hoch Matthias¹,Zack Julia²,Quinlan Michelle²,Huth Felix¹,Forte Sofia³,Dodd Stephanie⁴,Aimone Paola³,Hourcade‐Potelleret Florence¹

Affiliation:

1. Novartis Pharma AG Novartis Institutes for Biomedical Research Basel Switzerland

2. Novartis Pharmaceuticals East Hanover New Jersey USA

3. Novartis Pharma AG Basel Switzerland

4. Novartis Pharmaceuticals Novartis Institutes for Biomedical Research Cambridge Massachusetts USA

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1019

Reference22 articles.

1. Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer

2. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

3. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

4. A Myristoyl/Phosphotyrosine Switch Regulates c-Abl

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation;Clinical Pharmacokinetics;2024-09-07

2. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03

3. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia;Pharmaceutics;2023-10-26

4. Asciminib - ABL Kinase Inhibitor in the Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia: Chemistry and Pharmacology Perspectives;Mini-Reviews in Organic Chemistry;2023-10-17

5. Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket;Folia Pharmacologica Japonica;2023-05-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3